Literature DB >> 15655293

The different roles of 5-HT(2) and 5-HT(3) receptors on antinociceptive effect of paroxetine in chemical stimuli in mice.

Murat Kesim1, Erdem N Duman, Mine Kadioglu, Ersin Yaris, Nuri I Kalyoncu, Nesrin Erciyes.   

Abstract

Serotonin (5-HT) is known to be an important mediator in pain modulation. Some centrally acting agents, like selective serotonin reuptake inhibitors (SSRIs), modulate pain. Activation of the endogenous opioid mechanisms or potentiation of analgesic effect by serotonergic and/or noradrenergic pathways might be involved in antinociception of SSRIs. However, peripheral mechanisms of nociception are not clear. In this study, the antinociceptive effect of paroxetine, its interaction with the opioidergic system and serotonin receptors were tested using the writhing test in mice. Paroxetine (5, 10, 20 mg/kg) induced an antinociceptive effect following i.p. administration in writhing test. For the groups in which the antagonists were tested, the dose of paroxetine that caused a significant and equipotent analgesic effect similar to 0.5 mg/kg morphine was selected. Naloxone significantly antagonized the antinociceptive effects of both paroxetine and morphine in a similar pattern and magnitude. Ketanserin (5-HT(2)-receptor antagonist) or ondansetron (5-HT(3)-receptor antagonist) alone did not alter the nociceptive action of acetic acid. While the antinociceptive effect of paroxetine was highly potentiated by ketanserin, ondansetron reduced that antinociception. In conclusion, our results indicate that the antinociceptive effect of paroxetine mainly depends on central opioidergic and serotonergic mechanisms. Peripheral serotonergic mechanisms/receptors may contribute to this antinociceptive effect, especially by 5-HT(3)-receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655293     DOI: 10.1254/jphs.fp0040153

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  7 in total

1.  Modification of the behavioral effects of morphine in rats by serotonin 5-HT₁A and 5-HT₂A receptor agonists: antinociception, drug discrimination, and locomotor activity.

Authors:  Jun-Xu Li; Aparna P Shah; Sunny K Patel; Kenner C Rice; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2012-09-20       Impact factor: 4.530

2.  Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

Authors:  Oliver Kummer; Felix Hammann; Claudine Moser; Olivier Schaller; Jürgen Drewe; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2010-09-21       Impact factor: 2.953

3.  Molecular interactions between general anesthetics and the 5HT2B receptor.

Authors:  Felipe Matsunaga; Lu Gao; Xi-Ping Huang; Jeffery G Saven; Bryan L Roth; Renyu Liu
Journal:  J Biomol Struct Dyn       Date:  2013-12-23

4.  Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys.

Authors:  David R Maguire; Jun-Xu Li; Wouter Koek; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2012-07-27       Impact factor: 4.530

5.  The role of serotonergic and catecholaminergic systems for possible antidepressant activity of apigenin.

Authors:  Mohammad J Al-Yamani; Syed Mohammed Basheeruddin Asdaq; Abdulhakeem S Alamri; Walaa F Alsanie; Majid Alhomrani; Abdulkhaliq J Alsalman; Mohammed Al Mohaini; Maitham A Al Hawaj; Amani A Alanazi; Khulud D Alanzi; Mohd Imran
Journal:  Saudi J Biol Sci       Date:  2021-11-12       Impact factor: 4.219

6.  Paroxetine increases delta opioid responsiveness in sensory neurons.

Authors:  Allison Doyle Brackley; Nathaniel A Jeske
Journal:  eNeuro       Date:  2022-07-25

7.  Computational Methods for the Identification of Molecular Targets of Toxic Food Additives. Butylated Hydroxytoluene as a Case Study.

Authors:  Valentina Tortosa; Valentina Pietropaolo; Valentina Brandi; Gabriele Macari; Andrea Pasquadibisceglie; Fabio Polticelli
Journal:  Molecules       Date:  2020-05-09       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.